Abstract:
Mirus Bio Corporation announced today it has entered into a two year, multimillion dollar agreement with Pfizer Inc. to investigate and optimize gene silencing methods in animal models. The studies will utilize Mirus Bio's nucleic acid delivery platforms to target and suppress the expression of genes of interest to Pfizer.